The Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on Early Complications and Graft-Versus-Host Disease (GVHD) in Allogeneic Stem Cell Transplantation (ASCT) Recipients

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2023 Oct 2

PMID 37779681

Authors

Lale Aydin Kaynar

Zubeyde Nur Ozkurt

Affiliations

Soon will be listed here.

Abstract

Objectives Granulocyte colony-stimulating factor (G-CSF) is commonly used to accelerate neutrophil recovery after allogeneic stem cell transplantation (ASCT) in most transplant centers. There was no consensus on the optimal use of G-CSF after ASCT. Although we use G-CSF to minimize morbidity and mortality, G-CSF can increase the risk of graft-versus-host disease (GVHD). In our study, we want to show the effect of prophylactic G-CSF on infection frequency, neutrophil and platelet engraftment, the duration of neutropenia, the development of GVHD, hospitalization time, and transplant-related mortality (TRM) after ASCT. Materials and methods One hundred (71 males and 29 females) patients who did not receive G-CSF and 100 (58 males and 42 females) patients who received prophylactic G-CSF were included in the study. Results Age, diagnosis, the time between diagnosis and transplantation, preparation regimen, donor type, and the number of infused cluster of differentiation (CD) 34+ cells were not different in both groups (p>0.05). The frequency of female patients was higher in the group receiving G-CSF. Febrile neutropenia was more frequent in patients who did not receive G-CSF. Neutrophil engraftment and platelet engraftment were detected longer in patients not receiving G-CSF. The frequency of veno-occlusive disease (VOD) and hyperacute, chronic, and acute GVHD was not different in both groups (p>0.05). One hundred-day TRM and five-year overall survival (OS) were similar in the two groups (p>0.05). Conclusions Our study supports that G-CSF usage does not cause an increase in the frequency of GVHD and has a positive effect on the process by accelerating myeloid engraftment. In light of the data in our study, we can say that the use of G-CSF should be investigated in a randomized controlled clinical trial.

References

Nemunaitis J, Buckner C, Appelbaum F, Higano C, Mori M, Bianco J . Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood. 1991; 77(9):2065-71. View

Ho V, Mirza N, Junco Dd D, Okamura T, Przepiorka D . The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Bone Marrow Transplant. 2003; 32(8):771-5. DOI: 10.1038/sj.bmt.1704228. View

Trivedi M, Martinez S, Corringham S, Medley K, Ball E . Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009; 43(12):895-908. DOI: 10.1038/bmt.2009.75. View

Mohty M, Faucher C, Blaise D . Graft-versus-host-disease and granulocyte colony-stimulating factor administration after allogeneic stem cell transplantation. Leukemia. 2005; 19(4):500-3. DOI: 10.1038/sj.leu.2403660. View

Gupta A, Meena J, Haldar P, Tanwar P, Seth R . Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res. 2021; 11(5):544-563. PMC: 8610798. View

Khoury H, Loberiza Jr F, Ringden O, Barrett A, Bolwell B, Cahn J . Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2005; 107(4):1712-6. PMC: 1895414. DOI: 10.1182/blood-2005-07-2661. View

Trivedi M, Martinez S, Corringham S, Medley K, Ball E . Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2009; 17(2):85-90. DOI: 10.1177/1078155209354932. View

Singh V, Jang H, Kim S, Ayash L, Alavi A, Ratanatharathorn V . G-CSF use post peripheral blood stem cell transplant is associated with faster neutrophil engraftment, shorter hospital stay and increased incidence of chronic GVHD. Leuk Lymphoma. 2020; 62(2):446-453. DOI: 10.1080/10428194.2020.1827244. View

Schriber J, Chao N, Long G, Negrin R, Tierney D, Lucas K . Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood. 1994; 84(5):1680-4. View

10.

Sarici A, Erkurt M, Kuku I, Kaya E, Berber I, Bicim S . The effect of G-CSF used after allogeneic hematopoietic stem cell transplantation on engraftment times and platelet suspension replacement numbers. Transfus Apher Sci. 2022; 61(6):103482. DOI: 10.1016/j.transci.2022.103482. View

11.

Link H . Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF). Support Care Cancer. 2022; 30(9):7067-7077. PMC: 9225876. DOI: 10.1007/s00520-022-07103-5. View

12.

Torres Gomez A, Jimenez M, Alvarez M, Rodriguez A, Martin C, Garcia M . Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation. A prospective randomized study. Ann Hematol. 1995; 71(2):65-70. DOI: 10.1007/BF01699248. View

13.

Malek A . Time to revisit the use of G-CSF after allogeneic haematopoietic cell transplantation in COVID-19 era?. Br J Cancer. 2021; 124(7):1183. PMC: 7781165. DOI: 10.1038/s41416-020-01195-8. View

14.

Dekker A, Bulley S, Beyene J, Dupuis L, Doyle J, Sung L . Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006; 24(33):5207-15. DOI: 10.1200/JCO.2006.06.1663. View

15.

Himmelmann B, Himmelmann A, Furrer K, Halter J, Schanz U . Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial. Bone Marrow Transplant. 2002; 30(8):491-6. DOI: 10.1038/sj.bmt.1703708. View

16.

Remberger M, Naseh N, Aschan J, Barkholt L, LeBlanc K, Svennberg P . G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant. 2003; 32(2):217-23. DOI: 10.1038/sj.bmt.1704108. View

17.

Ciernik I, Schanz U, Gmur J . Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant. 1999; 24(2):147-51. DOI: 10.1038/sj.bmt.1701872. View

18.

Ringden O, Labopin M, Gorin N, Le Blanc K, Rocha V, Gluckman E . Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for.... J Clin Oncol. 2003; 22(3):416-23. DOI: 10.1200/JCO.2004.06.102. View